Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally.
Safety and tolerability profile observed, consistent with prior clinical studies in the general type 2 diabetes population Based on the results, Sumitomo Pharma is planning to conduct discussions ...
Sumitomo Pharma America (formerly Sunvion) has said that its ulotaront (SEP-363856), a novel trace amine-associated receptor 1 (TAAR1) agonist with serotonin 5-HT1A agonist activity, was unable to ...
Sumitomo Pharma America Inc. is conducting layoffs among employees that report to its headquarters in Marlborough. Last year, Sumitomo cut nearly 600 jobs in Massachusetts. Sumitomo Pharma America ...
Sumitomo generated $1.64 billion between April 1, 2023, and Dec. 31, 2023, a decline from $3.22 billion during the same period in 2022, according to Sumitomo Pharma’s third quarter report ending ...
Sumitomo already held around 52% of the company ahead of the new offer – which values Myovant at around $2.9 billion – and is spending $1.7 billion to gain 100% ownership of its shares.
Japan stocks were higher after the close on Thursday, as gains in the Paper & Pulp, Marine Transport and Gas & Water sectors ...
Delirium, a confused mental state, is common among older hospitalized adults, which increases the risks of falls and dementia ...
Sumitomo Pharma was founded in 1897 and operates in Osaka, Japan. The company engages in the sector 'Pharmaceuticals, Medicinal Chemical & Botanical Products' (ISIC: 2100). This industry belongs ...
Safety and tolerability profile observed, consistent with prior clinical studies in the general type 2 diabetes population Based on the results, Sumitomo Pharma is planning to conduct discussions with ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...